pembrolizumab
merck
['pembro', 'lymsm']
initial data from keynote-c11 of pembro+chemo in advanced-stage chl. 146 pts, median f/u 4 mos. 84% ipet3 neg after sequential pembro --&gt; avd x 2. few gr3 aes so far. dr. advani argues that pembro lead-in may improve performance status vs concurrent tx. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????